{"id":118014,"date":"2026-08-20T15:30:14","date_gmt":"2026-08-20T15:30:14","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/118014\/"},"modified":"2026-08-20T15:30:14","modified_gmt":"2026-08-20T15:30:14","slug":"novartis-swxnovn-trades-at-a-30-premium-after-esc-abstract-update","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/118014\/","title":{"rendered":"Novartis (SWX:NOVN) Trades At A 30% Premium After ESC Abstract Update"},"content":{"rendered":"\n

Find your next quality investment<\/a> with Simply Wall St’s easy and powerful screener, trusted by over 7 million individual investors worldwide. <\/p>\n

Novartis (SWX:NOVN) is drawing fresh attention after announcing plans to present data from 10 cardiovascular abstracts at the 2026 European Society of Cardiology Congress, spanning LDL cholesterol, atrial fibrillation and heart failure. <\/p>\n

See our latest analysis for Novartis.<\/a> <\/p>\n

Alongside the upcoming ESC data, Novartis has seen firm price momentum, with a 1-month share price return of 3.27% and a year to date share price return of 17.16%. The 5-year total shareholder return of 92.48% points to gains building over a longer period. <\/p>\n

If this kind of healthcare science focus appeals to you, it could be a good moment to widen your watchlist with a dedicated screener of 133 healthcare AI stocks<\/a> <\/p>\n

After a strong recent run and a large implied gap to some intrinsic value estimates, the key issue for Novartis now is simple. Does the current price still offer an attractive balance between risk and potential reward? <\/p>\n

Most Popular Narrative: 30.1% Overvalued <\/p>\n

The most followed narrative for Novartis puts fair value at CHF97.71, well below the last close at CHF127.12. That gap rests on several specific business assumptions. <\/p>\n

The strategy of lifting long term revenue expectations through bolt on deals such as Avidity and Tourmaline adds meaningful near term R and D and development spending. If pivotal data or launches underperform, the planned step up in future sales may not fully offset the 1 to 2 percentage point core margin dilution and could cap earnings progress. <\/p>\n

Read the complete narrative.<\/a> <\/p>\n

It may be useful to consider what earnings path and margin profile are built into that CHF97.71 fair value. The narrative leans on measured revenue growth, firmer profitability and a lower future earnings multiple. <\/p>\n

Result: Fair Value of CHF97.71 (OVERVALUED) <\/p>\n

Have a read of the narrative in full and understand what’s behind the forecasts.<\/a> <\/p>\n

However, there are still clear risks for this Novartis narrative if priority brands grow faster than expected or if radioligand and biologics margins remain firmly supported. <\/p>\n

Find out about the key risks to this Novartis narrative.<\/a> <\/p>\n

Another View on Novartis Using Market Ratios <\/p>\n

The narrative fair value for Novartis at CHF97.71 points to an overvalued stock, yet the current P\/E of 23.8x tells a different story. It is higher than the European pharmaceuticals average of 21.6x, but well below a fair ratio of 38.7x. Is the market underestimating upside or correctly pricing in risk? <\/p>\n

See what the numbers say about this price \u2014 find out in our valuation breakdown.<\/a> <\/p>\n

\"SWX:NOVN<\/a> SWX:NOVN P\/E Ratio as at Aug 2026 Next Steps <\/p>\n

With sentiment on Novartis clearly mixed, you may want to look through the numbers and narratives yourself, then weigh up the 3 key rewards and 1 important warning sign<\/a> <\/p>\n

Looking for more investment ideas beyond Novartis? <\/p>\n

If you are serious about building a stronger portfolio alongside Novartis, do not stop at one stock. Use a few focused screens to uncover fresh opportunities. <\/p>\n

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. <\/p>\n

Companies discussed in this article include NOVN.SW<\/a>. <\/p>\n

Have feedback on this article? Concerned about the content? Get in touch<\/a> with us directly. Alternatively, email editorial-team@simplywallst.com<\/a> <\/p>\n","protected":false},"excerpt":{"rendered":"Find your next quality investment with Simply Wall St’s easy and powerful screener, trusted by over 7 million…\n","protected":false},"author":2,"featured_media":118015,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[127],"tags":[1104,3795,206,1271],"class_list":["post-118014","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novartis","tag-fair-value","tag-intrinsic-value","tag-novartis","tag-total-shareholder-return"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/117128555731709523","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/118014","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=118014"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/118014\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/118015"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=118014"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=118014"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=118014"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}